Keros Therapeutics (KROS) shares dropped 70% in recent premarket activity after the company said Thursday that it voluntarily halted dosing in the 3 mg/kg and 4.5 mg/kg treatment arms of its phase 2 TROPOS trial of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension.
The decision was based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial, the company said.
The company plans to work with investigators, the US Food and Drug Administration and other relevant regulatory authorities to address the findings as quickly as possible.
Dosing in the 1.5 mg/kg treatment arm of the trial remains ongoing following the completion of a risk and benefit assessment.
Keros expects to present topline data from all treatment arms in the trial in Q2 of 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。